Aribio Signs 34 Billion Won Export Contract for Korean-Made Filler, Accelerating Revenue Growth

Aribio announced on September 19 that it has signed a hyaluronic acid filler export contract worth a total of 27.3 billion won with Stern Medical, a global medical device distribution specialist.

Stern Medical recorded 47 billion won in sales last year, leveraging its global sales network and distribution expertise in the medical device and skin booster sectors. Through this contract, Aribio plans to expand exports primarily focusing on its filler brand Bidan® line. The company has secured an advance payment equivalent to 10% of the expected first-year sales and confirmed the initial export volume.

Prior to this, Aribio also signed a large-scale export contract with Brazil, the largest aesthetic medical market in South America. Under this agreement, Aribio will supply fillers worth approximately 5 million US dollars (6.6 billion won) annually to HMD Brasil, a major Brazilian medical device distributor.

Brazil is the third-largest market in the world for aesthetics and plastic surgery, and demand for fillers and cosmetic procedures has been rapidly increasing. By meeting the stringent licensing standards of local regulatory authorities, Aribio has established a long-term export line with Brazil, the largest market in South America, as a strategic hub.

HMD Brasil is a Brazilian medical device and hospital supplies distribution company established in 2011. With its headquarters in Luziania and a logistics hub in Sao Paulo, it operates a nationwide supply chain. The company has a strong presence in the public procurement market targeting state governments and health authorities in Brazil.

Currently, Aribio is expanding its revenue portfolio into the medical device sector, including electronic medicines and high-performance aesthetic medical devices, while simultaneously developing new drugs such as AR1001, which is undergoing global Phase 3 clinical trials. In particular, through more than 10 years of research and development (R&D) and investment, the company has established a global export foundation for aesthetic medical devices such as skin boosters and fillers.

The company has demonstrated the safety and efficacy of its proprietary fillers through clinical research with university hospitals, and published the results in international academic journals. Aribio has also achieved international-level production capabilities and facilities by obtaining certifications for Good Manufacturing Practice (GMP) and the Medical Device Quality Management System (ISO13485).

Aribio is currently in the process of obtaining certification for its facial hyaluronic acid filler in line with the European Union Medical Device Regulation (CE-MDR) transition, as well as quality management certification that meets the standards of the Medical Device Single Audit Program (MDSAP). MDSAP is an international standard that enables a single audit to address the quality review requirements of major regulatory agencies in the United States (FDA), Canada, Brazil, Australia, and Japan, playing a crucial role in entering the global market.

Seo Boseung, Director of Aribio Medical Device Research Institute, stated, "This export contract is a meaningful achievement that confirms the technological capabilities and competitiveness of our domestically developed filler in the global market. To proactively respond to the surging worldwide demand for aesthetic medical procedures, we will secure US FDA and European CE certifications as early as possible and use them as key drivers for export expansion and revenue growth."

Meanwhile, Aribio is currently pursuing a merger with Kosdaq-listed company Solux, with the merger date set for January 20, 2026.

This content was produced with the assistance of AI translation services.